Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

期刊论文
发表日期：

2024年3月25日

查看全文

Yukinori Ozaki,
Takamichi Yokoe,
Tetsuhiro Yoshinami,
Kazuki Nozawa,
Hiroshi Nishio,
Kenji Tsuchihashi,
Eiki Ichihara,
Yuji Miura,
Makoto Endo,
Shingo Yano,
Dai Maruyama,
Nobuyuki Susumu,
Munetaka Takekuma,
Takashi Motohashi,
Mamoru Ito,
Eishi Baba,
Nobuaki Ochi,
Toshio Kubo,
Keita Uchino,
Takahiro Kimura,
Yutaro Kamiyama,
Shinji Nakao,
Shinobu Tamura,
Hitomi Nishimoto,
Yasuhisa Kato,
Atsushi Sato,
Toshimi Takano

摘要

Introduction

The timing of prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) administration during cancer chemotherapy varies, with Day 2 and Days 3–5 being the most common schedules. Optimal timing remains uncertain, affecting efficacy and adverse events. This systematic review sought to evaluate the available evidence on the timing of prophylactic pegylated G-CSF administration.

Methods

Based on the Minds Handbook for Clinical Practice Guideline Development, we searched the PubMed, Ichushi-Web, and Cochrane Library databases for literature published from January 1990 to December 2019. The inclusion criteria included studies among the adult population using pegfilgrastim. The search strategy focused on timing-related keywords. Two reviewers independently extracted and assessed the data.

Results

Among 300 initial search results, only four articles met the inclusion criteria. A meta-analysis for febrile neutropenia incidence suggested a potential higher incidence when pegylated G-CSF was administered on Days 3–5 than on Day 2 (odds ratio: 1.27, 95% CI 0.66–2.46, p = 0.47), with a moderate certainty of evidence. No significant difference in overall survival or mortality due to infections was observed. The trend of severe adverse events was lower on Days 3–5, without statistical significance (odds ratio: 0.72, 95% CI 0.14–3.67, p = 0.69) and with a moderate certainty of evidence. Data on pain were inconclusive.

Conclusions

Both Day 2 and Days 3–5 were weakly recommended for pegylated G-CSF administration post-chemotherapy in patients with cancer. The limited evidence highlights the need for further research to refine recommendations.